Abbott Laboratoriesvs.Natera
ABT vs NTRA · both in Diagnostics, part of the Medicine, pharma & life science value chain: Tests, imaging and assays that support clinical decision-making.
Abbott Laboratories is about 4.3× larger than Natera by market cap; year to date, Natera leads (+43.1% vs −6.9%).
Side by side
| ABT | NTRA | |
|---|---|---|
| Market cap | $193B | $44.6B |
| Price | $116.13 | $336.71 |
| Today | −0.5% | +2.7% |
| Return YTD | −6.9% | +43.1% |
| Return 1Y | −12.0% | +97.9% |
| P/E | 35.5 | — |
| P/S | 4.1 | 16.5 |
| P/B | 3.8 | 24.5 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Abbott LaboratoriesABT
In vitro diagnostics, medical devices that include the Libre glucose sensors, nutrition products and generic medicines: Abbott runs all four.
Full ABT profile →NateraNTRA
Genetic testing put to three uses: Panorama screens pregnancies, Signatera works in oncology, and a third line covers transplant medicine.
Full NTRA profile →More ABT & NTRA comparisons
Other head-to-heads in the Diagnostics segment.
See where ABT and NTRA sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →